A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Ravulizumab (Primary)
- Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
Most Recent Events
- 26 Aug 2022 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 22 Jul 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 16 Sep 2021 Status changed from active, no longer recruiting to discontinued (as study met futility bar at interim analysis)